Vol. 19 No. 1 (2020)
Literature Review

Inflammatory bowel disease and women’s sexual and reproductive health: a narrative review

PDF
  • Sara M. B. Cunha,
  • Maria C. F. Carneiro,
  • Cátia D. Rodrigues,
  • Cátia L. S. N. S. Rasteiro,
  • Teresa P. Teles
Sara M. B. Cunha
Gynaecology and Obstetrics Department, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal
Maria C. F. Carneiro
Gynaecology and Obstetrics Department, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal.
Cátia D. Rodrigues
Gynaecology and Obstetrics Department, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal.
Cátia L. S. N. S. Rasteiro
Gynaecology and Obstetrics Department, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal.
Bio
Teresa P. Teles
Gynaecology and Obstetrics Department, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal.
Bio
DOI: https://doi.org/10.12957/bjhbs.2020.53531

Published 2020-07-03

Keywords

  • Inflammatory bowel disease,
  • Sexual health,
  • Reproduction,
  • Pregnancy,
  • Breastfeeding

How to Cite

1.
Sara M. B. Cunha, Maria C. F. Carneiro, Cátia D. Rodrigues, Cátia L. S. N. S. Rasteiro, Teresa P. Teles. Inflammatory bowel disease and women’s sexual and reproductive health: a narrative review. BJHBS [Internet]. 2020 Jul. 3 [cited 2024 Oct. 11];19(1):48-56. Available from: https://bjhbs.hupe.uerj.br/bjhbs/article/view/111

Copyright (c) 2020 Brazilian Journal of Health and Biomedical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Introduction: Inflammatory bowel disease is a chronic idiopathic condition involving the gastrointestinal tract. The disease prevalence is increasing worldwide, affecting women in childbearing age. Objective: Clinical and practical review of the women´s sexual and reproductive health in inflammatory bowel disease with focus in gynaecological and obstetrical management. Materials and Methods: In this article we review sexual and reproductive health issues in women with inflammatory bowel disease in all life stages and the main particularities of the approach of inflammatory bowel disease in pregnancy and breastfeeding. Results and Conclusion: Fertility in women without disease activity is not decreased comparing to general population, but despite research is inconsistent there are reports of increased risk of small for gestational age, preterm delivery, low Apgar score, congenital anomalies, intrauterine death, miscarriage, venous thromboembolism and preeclampsia. To improve obstetric outcomes, a period of 3 to 6 months of disease remission is recommended before conception. Medication adjustment may be necessary, and supplementation should be adapted. A multidisciplinary approach and a comprehensive knowledge of the disease through all women life stages allows a better health care.

PDF

Metrics

Metrics Loading ...

References

  1. Huang VW, Chang HJ, Kroeker KI, et al. Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education. Canadian journal of gastroenterology & hepatology. 2016;2016:6193275.
  2. Kokoszko-Bilska A, Sobkiewicz S, Fichna J. Inflammatory bowel diseases and reproductive health. Pharmacological reports: PR. 2016;68(4):859-64.
  3. Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150(3):734-57.e1.
  4. Waszczuk E, Waszczuk K, Bohdanowicz-Pawlak A, et al. Women with inflammatory bowel diseases have a suboptimal cervical cancer screening rate and are not aware of the recommended human papilloma virus vaccine. Gynecological Endocrinology. 2018;34(8):656-8.
  5. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. The American journal of gastroenterology. 2008;103(3):631-6.
  6. Reich JS, Farraye FA, Wasan SK. Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New? Digestive diseases and sciences. 2016;61(8):2205-16.
  7. van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9(2):107-24.
  8. Contraceptive choices for women with inflammatory bowel disease. The journal of family planning and reproductive health care. 2003;29(3):127-35.
  9. Bonthala N, Kane S. Updates on Women’s Health Issues in Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2018;16(1):86-100.
  10. Freour T, Miossec C, Bach-Ngohou K, Dejoie T, et al. Ovarian reserve in young women of reproductive age with Crohn’s disease. Inflammatory bowel diseases. 2012;18(8):1515-22.
  11. Brah TK, Abel DE. Inflammatory Bowel Disease and Pregnancy. Topics in Obstetrics & Gynecology. 2017;37(17):1-7.
  12. Hashash JG, Kane S. Pregnancy and Inflammatory Bowel Disease. Gastroenterology & hepatology. 2015;11(2):96-102.
  13. Monsen U, Broström O, Nordenvall B, et al. Prevalence of Inflammatory bowel disease among relatives of patients with ulcerative colitis. Scandinavian journal of gastroenterology. 1987;22(2):214-8.
  14. Fielding JF. The relative risk of Inflammatory bowel disease among parents and siblings of Crohn’s disease patients. Journal of clinical gastroenterology. 1986;8(6):655-7.
  15. Direção Geral da Saúde. Vigilância de Gravidez de Baixo Risco. Lisboa, 2015
  16. Julsgaard M. Adherence to medical treatment in relation to pregnancy, birth outcome & breastfeeding behavior among women with Crohn’s disease. Danish medical journal. 2016;63(7).
  17. Abdul Sultan A, West J, Ban L, et al. Adverse Pregnancy Outcomes Among Women with Inflammatory Bowel Disease: A Population-Based Study from England. Inflammatory bowel diseases. 2016;22(7):1621-30.
  18. Pedersen N, Bortoli A, Duricova D, et al. The course of Inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO‐EpiCom Study of 209 pregnant women. Alimentary pharmacology & therapeutics. 2013;38(5):501-12.
  19. Boyd HA, Basit S, Harpsøe MC, et al. Inflammatory bowel disease and risk of adverse pregnancy outcomes. PLoS One. 2015;10(6):e0129567.
  20. Djokanovic N, Klieger-Grossmann C, Pupco A, et al. Safety of infiximab use during pregnancy. Reproductive toxicology. 2011;32(1):93-7.
  21. Julsgaard M, Hvas CL, Gearry RB, et al. Fecal Calprotectin is not afected by pregnancy: clinical implications for the management of pregnant patients with inflammatory bowel disease. Inflammatory bowel diseases. 2017;23(7):1240-6.
  22. Shitrit AB-G, Grisaru-Granovsky S, Ya’acov AB, et al. Management of Inflammatory bowel disease during pregnancy. Digestive diseases and sciences. 2016;61(8):2194-204.
  23. Direção geral de saúde: Aporte de iodo em mulheres na preconceção, gravidez e amamentação. Lisboa, 2013, pp 1-6.
  24. Yakut M, Üstün Y, Kabaçam G, et al. Serum vitamin B12 and folate status in patients with Inflammatory bowel diseases. European journal of internal medicine. 2010;21(4):320-3.
  25. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron defciency and anemia in Inflammatory bowel diseases#. Inflammatory bowel diseases. 2007;13(12):1545-53.
  26. Poturoglu S, Ormeci AC, Duman AE. Treatment of pregnant women with a diagnosis of Inflammatory bowel disease. World journal of gastrointestinal pharmacology and therapeutics. 2016;7(4):490.
  27. Gaidos JKJ, Kane SV. Sexuality, Fertility, and Pregnancy in Crohn’s Disease. Gastroenterology clinics of North America. 2017;46(3):531-46.
  28. William J. Sandbor. A SPECIAL MEETING REVIEW EDITION: Highlights in Crohn’s Disease and Ulcerative Colitis: May 19-22, 2012. San Diego.
  29. Gaidos JK, Kane SV. Managing IBD Therapies in Pregnancy Current treatment options in gastroenterology. 2017;15(1):71-83.
  30. Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case‐control ECCO‐EpiCom study, 2003–2006. Alimentary pharmacology & therapeutics. 2011;34(7):724-34.
  31. Østensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis research & therapy. 2006;8(3):209.
  32. Angelberger S, Reinisch W, Messerschmidt A, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. Journal of Crohn’s and Colitis. 2011;5(2):95-100.
  33. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease.
  34. and rheumatoid arthritis. The American journal of gastroenterology. 2004;99(12):2385.
  35. McConnell RA, Mahadevan U. Pregnancy and the patient with inflammatory bowel disease: fertility, treatment, delivery, and complications. Gastroenterology Clinics. 2016;45(2):285-301.
  36. Moens A, van Hoeve K, Humblet E, et al. Outcome of Pregnancies in Female Patients With Infammatory Bowel Diseases Treated With Vedolizumab. Journal of Crohn’s and Colitis. 2018;13(1):12-8.
  37. Lee KE, Jung S-A, Park SH, et al. Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity. Intestinal research. 2019;17(2):237.
  38. Chaparro M, Verreth A, Lobaton T, et al. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of infammatory bowel disease: Results from the multicenter european TEDDY study. The American journal of gastroenterology. 2018;113(3):396.
  39. The Transfer of Drugs and Other Chemicals Into Human Milk. Pediatrics. 2001;108(3):776-89.
  40. Bar-Oz B, Moretti ME, Boskovic R, O’Brien L, Koren G. The safety of quinolones--a meta-analysis of pregnancy outcomes. European journal of obstetrics, gynecology, and reproductive biology. 2009;143(2):75-8.
  41. McConnell RA, Mahadevan U. Use of immunomodulators and biologics before, during, and after pregnancy. Inflammatory bowel diseases. 2015;22(1):213-23.